Status
Conditions
Treatments
About
Tranexamic acid is thought to be a promising substitute for aprotinin when the latter has seceded in 2007. Yet the ideal dosage and dosing regimen of tranexamic acid in cardiopulmonary bypass cardiac surgery in Chinese population remains controversial. The current study includes patients receiving valvular replacement and coronary artery bypass surgery. Three dosage regimen of tranexamic acid is delivered and blood loss, transfusions and clinical outcomes are recorded.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
600 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Lihuan Li, MD; Jia Shi, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal